Alexander Drilon, MD presents data from the 2021 American Society of Clinical Oncology annual meeting from trials in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer treated with larotrectinib.
Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center
Advertisement
Articles by Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center
Alexander Drilon, MD presents updated results from a pooled analysis of TRK fusion-positive cancers treated with larotrectinib from the 2021 American Society of Clinical Oncology annual meeting.
Advertisement
Latest Updated Articles
Counseling Patients With NSCLC When KRAS is DetectedPublished: August 3rd 2020 | Updated:
Testing for KRAS Mutations in NSCLCPublished: August 3rd 2020 | Updated:
Current Management of Oncogene-Driven NSCLCPublished: August 3rd 2020 | Updated:
KRAS G12C Inhibition in Advanced NSCLC: MRTX849Published: August 3rd 2020 | Updated:
Systemic Therapy for KRAS+ Advanced NSCLCPublished: August 3rd 2020 | Updated:
KRAS Mutations in Solid TumorsPublished: August 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Emerging Data With Oral SERDs Reframe Frontline and Post–CDK4/6 Decisions in ER+ Breast Cancer
2
Relacorilant Plus Nab-Paclitaxel Meets OS End Point of ROSELLA Trial in PROC
3
Sofi-Cel Earns FDA Breakthrough Therapy Designation in Heavily Pretreated R/R T-ALL and T-LBL
4
Treatment Individualization Is Increasingly Vital With T-DXd Poised to Enter Early-Stage HER2+ Breast Cancer Paradigm
5